Opiranserin ( ; developmental code name INN VVZ-149) is a selective and combined glycine GlyT2 transporter blocker ( = 0.86 μM), IC 50 purine P2X 3 receptor antagonist ( IC = 0.87 μM), and 50 serotonin 5-HT antagonist ( 2A receptor = 1.3 μM) which is under development by Vivozon for the IC 50 intravenous treatment of postoperative pain.    As of April 2017, it is in  phase II clinical trials for this indication. The  of the drug was issued in 2017. INN
Pang MH, Kim Y, Jung KW, Cho S, Lee DH (2012). "A series of case studies: practical methodology for identifying antinociceptive multi-target drugs". Drug Discov. Today. 17 (9–10): 425–34. doi: 10.1016/j.drudis.2012.01.003. PMID 22269134.
^ a b
^ a b
"Opiranserin - Vivozon - AdisInsight". adisinsight.springer.com.
Nedeljkovic SS, Correll DJ, Bao X, Zamor N, Zeballos JL, Zhang Y, Young MJ, Ledley J, Sorace J, Eng K, Hamsher CP, Maniam R, Chin JW, Tsui B, Cho S, Lee DH (2017). "Randomised, double-blind, parallel group, placebo-controlled study to evaluate the analgesic efficacy and safety of VVZ-149 injections for postoperative pain following laparoscopic colorectal surgery". BMJ Open. 7 (2): e011035. doi: 10.1136/bmjopen-2016-011035. PMC . 5318554 PMID 28213593.